Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation

Tomoya Mita; Naoto Katakami; Toshihiko Shiraiwa; Hidenori Yoshii; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada; Sitagliptin Preventive Study of Intima-media Thickness Evaluation (SPIKE) Trial

doi:10.1111/jdi.12559

Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation

J Diabetes Investig. 2017 Mar;8(2):254-255. doi: 10.1111/jdi.12559.

Authors

Tomoya Mita¹, Naoto Katakami^{2

3}, Toshihiko Shiraiwa⁴, Hidenori Yoshii⁵, Masahiko Gosho⁶, Iichiro Shimomura², Hirotaka Watada¹; Sitagliptin Preventive Study of Intima-media Thickness Evaluation (SPIKE) Trial

Affiliations

¹ Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
² Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
³ Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Suita, Japan.
⁴ Shiraiwa Medical Clinic, Kashiwara, Osaka, Japan.
⁵ Department of Medicine, Diabetology & Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.
⁶ Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Abstract

Figure 1 shows differences in treatment-induced delta change in carotid IMT relative to baseline, according to various pre-defined risk factors for atherosclerosis. These data suggest that treatment with DPP-4 inhibitors seem to prevent the progression of carotid atherosclerosis regardless of disease burden.

Publication types

Letter

MeSH terms

Aged
Carotid Artery Diseases / diagnostic imaging
Carotid Artery Diseases / etiology
Carotid Artery Diseases / prevention & control*
Carotid Intima-Media Thickness
Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / pathology
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Female
Humans
Male
Middle Aged
Sitagliptin Phosphate / therapeutic use*
Treatment Outcome

Substances

Dipeptidyl-Peptidase IV Inhibitors
Sitagliptin Phosphate